Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
Anticancer Research · 2023
DOI: 10.21873/anticanres.16273 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2023. Verfasst von Marina Abe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan. Hauptthemen laut MEDLINE: Neutropenia, Thrombocytopenia, Ovarian Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND/AIM: In recent years, the usefulness of poly ADP-ribose polymerase (PARP) inhibitors as subsequent maintenance therapy with poly ADP-ribose polymerase (PARP) inhibitors has been reported. However, it has been reported shown that platinum-based chemotherapy has a low response rate and short progression-free survival for recurrent platinum-sensitive ovarian cancer during treatment with PARP inhibitor therapy. This retrospective study evaluated platinum-based chemotherapy with bevacizumab (BEV) followed by BEV maintenance in these recurrent patients. PATIENTS AND METHODS: Efficacy and safety were evaluated in 23 patients with ovarian, fallopian tube, or primary peritoneal cancer diagnosed with platinum-sensitive recurrence during PARP inhibitor treatment (administered from April 2019 to December 2022). Platinum-based chemotherapy included either paclitaxel with carboplatin, paclitaxel with cisplatin, docetaxel with carboplatin, or doxorubicin with carboplatin. BEV was administered in combination with any of these chemotherapies agents. Chemotherapy was administered for 6 cycles and BEV was administered up to 21 cycles. RESULTS: The median numbers of cycles of platinum-based chemotherapy and BEV administration were 6 and 8, respectively. Complete response was observed in four patients (17.4%), partial response in 15 (65.2%), stable disease in two (8.7%), and progressive disease in two (8.7%). Objective response and disease control rates were 82.6% and 91.3%, respectively. Grade 3 or higher hematological toxicity occurred in 8 patients, with leukopenia, neutropenia in 14, anemia in 5, and thrombocytopenia in 4. On the other hand, non-hematological toxicities included hypertension in three patients, proteinuria in two, constipation in one, and carboplatin hypersensitivity in four. Only one patient discontinued chemotherapy due to an adverse event of proteinuria. No treatment-related deaths occurred. CONCLUSION: Platinum-based chemotherapy with BEV followed by BEV maintenance for platinum-sensitive recurrence during PARP inhibitor treatment was shown to be efficacious and safe. This combination should be further evaluated in larger randomized clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan; tshoji@iwate-med.ac.jp.
- Department of Information Science, Iwate Medical University, Iwate, Japan.
- Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Aomori, Japan.
Zitieren
APA
Abe, M., Shoji, T., Chiba, Y., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Takahashi, F., Aida, T., & Baba, T. (2023). Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Research. https://doi.org/10.21873/anticanres.16273
Vancouver
Abe M, Shoji T, Chiba Y, Takatori E, Kaido Y, Nagasawa T, et al. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. Anticancer Research. 2023. doi:10.21873/anticanres.16273
BibTeX
@article{Abe2023,
author = {Abe, Marina and Shoji, Tadahiro and Chiba, Yohei and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Takahashi, Fumiaki and Aida, Takeshi and Baba, Tsukasa},
title = {Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16273}
}
EUVIMED